These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 934358)

  • 1. Effects of pretreatment with spironolactone of pharmacokinetics of 4'''-methyldigoxin in man.
    Abshagen U; Rennekamp H; Kuhlmann J
    Naunyn Schmiedebergs Arch Pharmacol; 1976; 292(1):87-92. PubMed ID: 934358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of spironolactone pretreatment on pharmacokinetics and metabolism of digitoxin in rats.
    VOHRINGER HF; Weller L; Rietbrock N
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 287(2):129-39. PubMed ID: 1143356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pretreatment with spironolactone on pharmacokinetics of 4'''-methyldigoxin in rats.
    Abshagen U
    Naunyn Schmiedebergs Arch Pharmacol; 1973; 278(1):91-100. PubMed ID: 4267969
    [No Abstract]   [Full Text] [Related]  

  • 4. Disposition of beta-methyldigoxin in man.
    Rietbrock N; Abshagen U; Bergmann K; Rennekamp H
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):105-14. PubMed ID: 1233258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of spironolactone in man.
    Abshagen U; Rennekamp H; Luszpinski G
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Dec; 296(1):37-45. PubMed ID: 1012347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of beta-methyldigoxin in healthy humans I: intravenous studies.
    Hinderling PH; Garrett ER; Wester RD
    J Pharm Sci; 1977 Feb; 66(2):242-53. PubMed ID: 839422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digoxin-interactions in man: spironolactone reduces renal but not biliary digoxin clearance.
    Hedman A; Angelin B; Arvidsson A; Dahlqvist R
    Eur J Clin Pharmacol; 1992; 42(5):481-5. PubMed ID: 1606994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of beta-methyldigoxin in healthy humans II: Oral studies and bioavailability.
    Hinderling PH; Garrett ER; Wester RC
    J Pharm Sci; 1977 Mar; 66(3):314-25. PubMed ID: 845795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability and pharmacokinetics of beta-methyldigoxin after multiple oral and intravenous doses.
    Rietbrock N; Guggenmos J; Kuhlmann J; Hess U
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):373-9. PubMed ID: 971702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone. I. Disposition and metabolism.
    Karim A; Zagarella J; Hribar J; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):158-69. PubMed ID: 1261153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new turbidometric digoxin immunoassay on the ADVIA 1650 analyzer is free from interference by spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Datta P; Dasgupta A
    Ther Drug Monit; 2003 Aug; 25(4):478-82. PubMed ID: 12883233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of spironolactone and potassium canrenoate in humans.
    Kojima K; Yamamoto K; Fujioka H; Kaneko H
    J Pharmacobiodyn; 1985 Mar; 8(3):161-6. PubMed ID: 4009408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H3-digitoxin and its metabolites following spironolactone pretreatment of rats.
    Castle MC; Lage GL
    Res Commun Chem Pathol Pharmacol; 1973 Sep; 6(2):601-12. PubMed ID: 4750104
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
    Krause W; Karras J; Seifert W
    Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
    Dasgupta A; Johnson MJ
    J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
    Dasgupta A; Johnson MJ; Sengupta TK
    J Clin Lab Anal; 2012 May; 26(3):143-7. PubMed ID: 22628228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into the pharmacokinetics of spironolactone.
    Overdiek HW; Hermens WA; Merkus FW
    Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The disposition of radioactivity after administration of the anthelminthic methyl-14C-5-cyclopropylcarbonyl-2-benzimidazole carbamate (ciclobendazole) to rats and dogs.
    Brodie RR; Mayo BC; Chasseaud LF; Hawkins DR
    Arzneimittelforschung; 1977; 27(3):593-8. PubMed ID: 577426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic studies on fluoro-alpha-acetyl-digoxin (author's transl)].
    Bodem G; Wirth K; Zimmer A
    Arzneimittelforschung; 1978; 28(2):322-5. PubMed ID: 580403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic behaviour of 4'''-methyldigoxin in man.
    Rennekamp H; Rennekamp C; Abshagen U; von Bergmann K; Rietbrock N
    Naunyn Schmiedebergs Arch Pharmacol; 1972; 273(1):172-4. PubMed ID: 4260801
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.